Key Stats for IDEXX Stock
- Current Price: $550.01
- Target Price (Mid): ~$946
- Street Target: ~$699
- Potential Total Return: ~72%
- Annualized IRR: ~13% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
IDEXX Laboratories (IDXX) closed at $550.01 on August 25, about 28% below its 52-week high of $769.98. Yet on August 13, the company spent a full day telling investors its growth engine is accelerating, not stalling. That gap is the story right now: the stock is priced for a slowdown while management guides for the opposite.
The occasion was new CEO Mike Erickson’s first Investor Day, three months after he took over from Jay Mazelsky in May. He used it to reaffirm a long-term algorithm of more than 10% organic revenue growth and roughly 15% average annual EPS growth, and to preview a new point-of-care platform, MultiCue Dx, that IDEXX will unveil at the VMX conference in Orlando in January 2027.
Why IDEXX Thinks Its Machines Get More Valuable After It Sells Them
The core of Erickson’s pitch is that IDEXX’s installed base appreciates rather than depreciates. Every year, the company pushes new tests to analyzers already on the counter, so the same box generates more revenue over time. Point-of-care lead Pooja Pathak quantified it: Catalyst has delivered a 2.5x expansion of economic value per placement since the launch of Catalyst One. Commercial chief George Fennell put the idea plainly: “A product is an asset that tends to depreciate in value over time. The IDEXX Catalyst has just taken on additional capability over time.”
CFO Andrew Emerson pointed to over 200,000 placement opportunities for core analyzers alone and roughly 10%-plus installed-base growth over time. Retention sits in the high 90% range, so each placement compounds. This is the mechanism the market is discounting, and the reason IDEXX has kept growing well above veterinary visit trends: in Q2 2026, CAG Diagnostics’ recurring revenue grew 10.3% organically even as U.S. same-store clinical visits fell 1.3%.
See historical and forward estimates for IDEXX stock (It’s free!) >>>
Cancer Testing and a European Proof Point
The biggest new-product lever is Cancer Dx, and the roadmap was tightened at the event. IDEXX is expanding it from a lymphoma test into a multi-cancer panel, adding mast cell tumor detection in September and hemangiosarcoma in December. Those three cover about 40% of canine cancers, with a path to 50% by 2028. IDEXX is holding a roughly $15 price point when the panel runs with blood work in its reference labs, deliberately removing the choice between running a panel and screening for cancer. Over 11,000 practices have run it, and 20% of those practices do not use IDEXX as their primary lab, meaning they broke their own workflow to access it.
Dr. Jo Malone, Founder and CEO of VetPartners Europe, described adding wellness blood testing to her group’s pet health plans and watching volumes jump more than 15x once clients were simply told it was included. “With more testing comes more testing,” she said, and she is now planning to fold Cancer Dx into those wellness panels. When a network of roughly 800 sites wires your newest test into its default protocol, adoption stops being theoretical.
Reference lab testing carries greater exposure to wellness visits, which fell 3.4% in the U.S. in Q2. Management assumes U.S. visits decline about 1.5% in the back half of 2026. If that softness drags on, the segment most tied to the cancer story is also the one most exposed to the headwind.
What the Reaffirmed Guidance Does to the Valuation
At $550, IDEXX trades around 35 times next-twelve-month earnings, down from a trailing multiple near 39 times and below where this business has historically traded. For a company reaffirming mid-teens EPS growth with high-90s retention and a return on invested capital in the 50%-plus range, that multiple assumes the growth algorithm breaks. The bet against IDEXX is really a bet that the vet-visit headwind eventually infects the recurring revenue base, and so far, the data cuts the other way.
The consensus mean target sits near $699, and the analyst split is genuinely divided: 4 Buys, 4 Outperforms, 5 Holds, and 1 Underperform. Barclays captured the tension when it cut its target to $710 from $800 on August 11 while keeping an Overweight rating, citing ongoing weakness in U.S. clinic traffic. The debate is not whether IDEXX is a great business.
See how IDEXX performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $550.01
- Target Price (Mid): ~$946
- Potential Total Return: ~72%
- Annualized IRR: ~13% / year
See analysts’ growth forecasts and price targets for IDEXX stock (It’s free!) >>>
TIKR’s mid-case model values IDEXX at around $946 by the end of 2030, roughly 72% above today’s price, or about 13% annualized over 4.3 years. The two revenue drivers are diagnostic utilization gains from the innovation cycle (Cancer Dx, inVue Dx cytology, and the new proBNP cardiac test) and continued instrument placements against that 200,000-plus runway. The margin driver is operating leverage, with IDEXX guiding to over 32% operating margin in 2026 and 50 to 100 basis points of annual expansion, carrying net income margin toward roughly 27% in the mid case. The primary risk is the one the stock is fixated on: a prolonged decline in U.S. clinical visits that caps the reference lab recovery.
On the upside, if the innovation flywheel and international expansion (where CAG recurring revenue grew nearly 12% organically in Q2) keep growth well above the end market, the model’s high case pushes the annualized return into the mid-teens. On the downside, if visits stay weak and the multiple keeps compressing, the low case still models around 8.5% annualized, because the recurring base grows regardless.
Conclusion
The next hard test is the Q3 print, expected in early November. The number that matters is not headline EPS but CAG Diagnostics’ recurring organic growth. If it holds near 10% while U.S. visits stay down around 1.5%, the Investor Day thesis is intact, and the discount is hard to justify. If recurring growth slips toward the visit trend, the bears finally have their evidence. After that comes the January VMX reveal of MultiCue Dx, the first read on IDEXX’s next platform.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in IDEXX?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up IDEXX, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track IDEXX alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
